# Sus Clinicals, Inc.

> Sus Clinicals, Inc. is a Cincinnati- and Chicago-based biotechnology company commercializing the Oncopig Cancer Model - a genetically engineered pig that develops human-like tumors on demand. Billed as the only FDA-cleared large animal cancer platform, the Oncopig carries KRAS and TP53 mutations found in more than half of human cancers, giving drug, device, and diagnostic developers a predictive testing ground that sits between the mouse and the human clinical trial. Alongside live animal supply, the company runs histology services and a tumor-tissue biorepository, and partners with CROs across the US and Europe.

- **Founded:** 2020
- **Headquarters:** Cincinnati, United States
- **Founders:** Jeffrey D. Weedman (Executive Chair & Co-Founder), Dr. Lawrence Schook (Chief Scientific Officer & Co-Founder)
- **Team size:** 18
- **Products:** Oncopig Cancer Model, Naive Oncopig Supply, Histology & Pathology Services, Tumor & Tissue Biorepository, Preclinical Study Services (via CRO partners)
- **Notable:** Developed and commercialized the only FDA-cleared large animal cancer model., Secured a $2M NIH SBIR grant (2023) and a $3.5M seed round (2024)., Became the exclusive global licensee of the Oncopig IP from the University of Illinois.

## Products & services

- **Oncopig Cancer Model** — A genetically engineered pig carrying KRAS-G12D and TP53-R167H mutations - found in more than 50% of human cancers - that develops site- and cell-specific tumors on demand, recapitulating the phenotype and physiology of human cancer. Marketed as the only FDA-cleared large animal cancer model.
- **Naive Oncopig Supply** — Live, naive Oncopigs shipped to customer facilities for in-house studies. Litters are typically available every 5 weeks and ship at roughly 8 weeks of age.
- **Histology & Pathology Services** — In-house histology producing digitized slides, IHC staining for targets of interest, antibody validation, and pathological interpretation.
- **Tumor & Tissue Biorepository** — A repository of formalin-fixed paraffin-embedded (FFPE) Oncopig tumor and tissue blocks, plus fresh, frozen, and liquid tissue samples and cell lines for in vitro work.
- **Preclinical Study Services (via CRO partners)** — Full-service preclinical drug, device, and diagnostic testing delivered through a network of preferred CRO partners in the US and Europe.

## Achievements

- Developed and commercialized the only FDA-cleared large animal cancer model.
- Secured a $2M NIH SBIR grant (2023) and a $3.5M seed round (2024).
- Became the exclusive global licensee of the Oncopig IP from the University of Illinois.
- Built an in-house histology capability and FFPE tumor biorepository.
- Established Oncopig models for multiple cancers including soft tissue sarcoma, pancreatic ductal adenocarcinoma, hepatocellular carcinoma, and bladder cancer.
- Cited in peer-reviewed studies showing Oncopig bladder cancer cells recapitulate human treatment responses in vitro.

## Latest updates

- **2024-07** — Dr. Jessicca M. Rege named Chief Executive Officer; Jeffrey D. Weedman moves to Executive Chair.
- **2024-01** — Closed a $3.5M seed funding round.
- **2023-09** — Announced a $2M SBIR research grant from the National Institutes of Health.
- **2024-03** — Peer-reviewed study in Frontiers in Oncology shows Oncopig bladder cancer cells recapitulate human bladder cancer treatment responses in vitro.

## Links

- Website: https://susclinicals.com
- LinkedIn: http://www.linkedin.com/company/susclinicals
- Twitter/X: https://twitter.com/susclinicals
- YouTube: https://www.youtube.com/@susclinicals57
- Facebook: https://www.facebook.com/Sus-Clinicals-104608361626141

---

Profile page: https://yespress.io/sus-clinicals-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-02